A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

Key Inclusion Criteria for Healthy Participants (Part 1)

• Participants who are of non-childbearing potential or are using acceptable contraception.
• Body mass index (BMI) and body weight within an acceptable range.
• Good general health based on medical history, physical examination, electrocardiogram (ECG), and laboratory assessments.

Key Disease-Agnostic Inclusion Criteria for Patient Participants (Part 1)

• BMI and body weight within an acceptable range.
• Adequate hematologic, renal, hepatic, immunologic, and lymphocyte parameters.

Key Disease-Specific Inclusion Criteria for Patient Participants (Part 1)

• Confirmed autoimmune disease with appropriate supporting autoantibody findings.
• Stable background therapy prior to dosing.
• Active moderate to severe disease consistent with protocol-defined disease activity criteria for:

• Systemic lupus erythematosus (SLE)
• Systemic sclerosis (SSc)
• Rheumatoid arthritis (RA)
• Sjögren's disease (SjD)

Key Inclusion Criteria for Rescreening Participants (Part 2)

• Meets Part 1 disease-agnostic inclusion criteria.
• Stable background autoimmune therapy prior to dosing.
• Ongoing active moderate to severe disease based on protocol-defined disease-specific criteria.

Key Exclusion Criteria for Parts 1 and 2

• Pregnant or breastfeeding participants.
• Recent vaccination within protocol-defined timelines.
• Clinically significant medical history or abnormal physical examination findings.
• Clinically significant cardiovascular abnormalities, including blood pressure, heart rate, syncope, or ECG findings.
• Prior or recent therapies or conditions that may interfere with study participation or safety evaluations.
• Severe pulmonary, renal, or cardiac disease, or clinically significant pulmonary hypertension.